View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2019	May 14, 2019
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	0001446159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		30,680,570
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and Cash Equivalents	$ 1,124,730	$ 162,152
Accounts Receivable	173,443	232,602
Notes Receivable (inclusive of $738,138 and $452,775 in advances to Helomics)	1,801,479	497,276
Inventories	289,023	241,066
Prepaid Expense and other assets	265,584	318,431
Total Current Assets	3,654,259	1,451,527
Notes Receivable		1,112,524
Fixed Assets, net	148,709	180,453
Intangibles, net	950,049	964,495
Lease Right-of-Use Assets	333,944
Total Assets	5,086,961	3,708,999
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	432,198	445,689
Note Payable – Bridge Loan Net of Discount of $646,524 and $969,786	1,812,037	1,327,942
Notes Payable – Net of Discount of $352,961 and $63,028	1,267,039	306,972
Accrued Expenses	797,599	1,279,114
Derivative Liability	353,210	272,745
Deferred Revenue	20,929	23,065
Current Lease Liability	78,819
Total Current Liabilities	4,761,831	3,655,527
Lease Liability	255,125
Total Liabilities	5,016,956	3,655,527
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 authorized, 17,360,144 and 14,091,748 outstanding	173,601	140,917
Additional paid-in capital	66,296,741	63,019,708
Accumulated Deficit	(66,401,129)	(63,107,945)
Total Stockholders' Equity	70,005	53,472
Total Liabilities and Stockholders' Equity	5,086,961	3,708,999
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series B Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 79,246 and 79,246 outstanding	$ 792	$ 792

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Notes receivable	$ 1,801,479	$ 497,276
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	17,360,144	14,091,748
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Bridge Loan [Member]
Discount of note payable	$ 646,524	$ 969,786
Notes Payable [Member]
Discount of note payable	352,961	63,028
Helomics Holding [Member]
Notes receivable	$ 738,138	$ 452,775

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 255,241	$ 411,593
Cost of goods sold	73,717	117,343
Gross margin	181,524	294,250
General and administrative expense	1,497,945	1,241,961
Operations expense	466,566	287,590
Sales and marketing expense	554,216	550,538
Total operating loss	2,337,203	1,785,839
Other income	53,432	27,655
Other expense	569,776	1,838
Loss on equity method investment	439,637
Net loss attributable to common shareholders	$ (3,293,184)	$ (1,760,022)
Loss per common share - basic and diluted (in dollars per share)	$ (0.21)	$ (0.15)
Weighted average shares used in computation - basic and diluted (in shares)	15,731,517	11,383,217

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Chief Executive Officer [Member] Common Stock [Member]	Chief Executive Officer [Member] Additional Paid-in Capital [Member]	Chief Executive Officer [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2017								$ 7,271	$ 69,432	$ 57,380,256	$ (54,765,045)	$ 2,691,913
Balance (in shares) at Dec. 31, 2017						647,819	79,246		6,943,283
Preferred conversion to common shares pursuant to private placement agreement								(6,479)				(6,479)
Preferred conversion to common shares pursuant to private placement agreement (in shares)						(647,819)
Preferred conversion to common shares pursuant to private placement agreement (in shares)									589,747
Preferred conversion to common shares pursuant to private placement agreement									$ 5,897	582		0
Shares issued pursuant to the public offering									$ 29,000	2,726,087		2,755,087
Shares issued (in shares)									2,900,000
Investment pursuant to Helomics 20% acquisition									$ 11,000	1,031,250		1,042,250
Investment pursuant to Helomics 20% acquisition (in shares)									1,100,000
Warrant exercises	$ 558	$ 55,238
Warrant exercises (in shares)	55,796
Vesting Expense										226,387		226,837
Net loss											(1,760,022)	(1,760,022)
Balance at Mar. 31, 2018								792	$ 118,040	61,622,067	(56,525,066)	5,215,833
Balance (in shares) at Mar. 31, 2018							79,246		11,804,073
Balance at Dec. 31, 2018								792	$ 140,917	63,019,708	(63,107,945)	53,472
Balance (in shares) at Dec. 31, 2018							79,246		14,091,748
Preferred conversion to common shares pursuant to private placement agreement
Preferred conversion to common shares pursuant to private placement agreement (in shares)									159,854
Preferred conversion to common shares pursuant to private placement agreement									$ 1,599	88,401		90,000
Shares issued pursuant to the public offering			$ 781	$ 49,219	$ 50,000				$ 28,638	2,401,071		2,429,709
Shares issued (in shares)			78,125						2,863,750
Vesting Expense										263,600		263,600
Net loss											(3,293,184)	(3,293,184)
Shares issued in forbearance agreement									$ 1,666	156,684		158,350
Shares issued in forbearance agreement (in shares)									166,667
Warrants issued pursuant to CEO note payable										318,058		318,058
Balance at Mar. 31, 2019								$ 792	$ 173,601	$ 66,296,741	$ (66,401,129)	$ 70,005
Balance (in shares) at Mar. 31, 2019							79,246		17,360,144

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flow from operating activities:
Net loss	$ (3,293,184)	$ (1,760,022)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	439,637
Depreciation and amortization	39,526	18,167
Vesting expense for stock options	263,600	226,387
Amortization of debt discount	468,564
Loss on valuation of equity-linked instruments	19,408
Changes in assets and liabilities:
Accounts receivable	59,159	(104,265)
Inventories	(47,957)	(7,511)
Prepaid expense and other assets	(3,273)	81,661
Accounts payable	(13,491)	45,847
Accrued expenses	21,494	(226,775)
Deferred revenue	(2,136)	32,193
Net cash used in operating activities	(2,048,653)	(1,694,318)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advance on notes receivable	(631,316)	(42,524)
Purchase of fixed assets		(32,789)
Transfer of fixed assets to inventory	9,863
Acquisition of intangibles	(3,198)	(24,029)
Net cash (used in) provided by investing activities:	(624,651)	145,629
Cash flow from financing activities:
Extinguishment of convertible debt	(93,827)
Proceeds from debt issuance	1,250,000
Proceeds from exercise of warrants into common stock		55,794
Issuance of common stock	2,479,709	2,959,509
Net cash provided by financing activities	3,635,882	3,015,303
Net increase in cash and cash equivalents	962,578	1,466,614
Cash at beginning of period	162,152	766,189
Cash at end of period	1,124,730	2,232,803
Non-cash transactions:
Bridge loan conversion into common stock	90,000
Forbearance settlement bridge loan	503,009
Additional warrants issued pursuant to CEO note payable	8,665
Conversion of preferred stock to common stock		6,479
Equity method investment - Helomics		$ 1,542,250

Note 1 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

the Company filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

March 31, 2019,

the Company had

17,360,144

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

) the Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of proprietary cleaning fluid and filters to users of its systems. In

April 2009,

the Company received

510

(k) clearance from the Food and Drug Administration (the “FDA”) to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement. On

April 4, 2019,

the Company completed the acquisition and is now the sole owner of Helomics – see Note

10.

The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over

149,000

tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc., to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis Inc., formed during the

first

quarter of

2018,

is presented as part of the unaudited condensed consolidated financial statements (“financial statements”).

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of

$66,401,129.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. In the

first

quarter the Company incurred negative cash flows from operations. Although the Company has attempted to curtail expenses, there is

guarantee that the Company will be able to reduce these expenses significantly, and expenses

may

need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.

The Company had cash and cash equivalents of

$1,124,730

as of

March 31, 2019

and needs to raise significant additional capital to meet its operating needs, pay debt obligations coming due, and fund the continued operating needs of Helomics; therefore, there is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-

with which the Company has raised approximately

$2.1

million in net proceeds in early

2019.

The Company

may

raise up to approximately

$5.0

million in additional gross proceeds, now that the Helomics acquisition is completed.

Since inception to

March 31, 2019,

the Company has raised approximately

$38,970,000

in equity and

$9,120,000

in debt financing. Equity raises include: a

January 2018

public offering with net proceeds of

$2,475,000;

and

March 2019

public offerings with net proceeds of

$1,112,000

and

$1,053,000.

Included in debt financing were raises in

September 2018

on senior secured promissory notes with net proceeds of

$1,815,000.

November 2018,

the Company received a loan from the CEO for

$370,000.

February 2019,

the Company received a loan from the CEO for

$950,000,

and in

March 2019

the Company received a loan from the CEO for

$300,000.

Interim Financial Statements

The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form

-K filed with the SEC on

April 1, 2019.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

Recent Accounting Developments

Accounting Policies and Estimates

The presentation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after

December 15, 2018.

Early adoption is permitted. The Company adopted the standard on

January 1, 2019,

using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. Upon adoption, the Company recognized

$353,007

of lease right-of-use (ROU) assets and liabilities for operating leases on its condensed consolidated balance sheet, of which,

$79,252

were classified as current liabilities. The adoption of ASU

2016

did

not

have a material impact on the Company’s consolidated results of operations or cash flows.

The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is

not

explicit in a lease, the Company utilizes its incremental borrowing rate for a period that closely matches the lease term.

See Note

– Leases

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventories

Inventories are stated at the net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	March 31, 2019		December 31, 2018

Finished goods	$	88,849	$	58,701
Raw materials		139,183		127,003
Work-In-Process		60,991		55,362
Total	$	289,023	$	241,066

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s fixed assets consist of the following:

	March 31, 2019		December 31, 2018
Computers and office equipment	$	205,758	$	204,903
Leasehold improvements		140,114		140,114
Manufacturing tooling		108,955		108,955
Demo equipment		74,529		85,246
Total		529,356		539,218
Less: Accumulated depreciation		380,647		358,765
Total Fixed Assets, Net	$	148,709	$	180,453

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was

$21,882

in the

three

months ended

March 31, 2019

and was

$14,496

for the

three

months ended

March 31, 2018.

Intangible Assets

Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was

$17,644

in the

three

months ended

March 31, 2019

and was

$3,671

in the

three

months ended

March 31, 2018.

The Company reviews identifiable intangible assets for impairment in accordance with ASC

360

—

Intangibles

—

Goodwill and Other

, whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are definite lived and currently solely the costs of obtaining licensing fees, trademarks, and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

There is

income tax provision in the accompanying statements of net loss due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2015

remain open to examination by federal and state tax authorities.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any

one

financial institution. The Company has credit risk concentration for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.

Segments

The Company has

two

operating segments; domestic and international sales. The segment revenues and net losses for the

three

-month period ended

March 31, 2019

are described in the table below. Substantially all of the Company’s revenues and expenses in the prior year were related to the domestic segment.

	Domestic			International			Totals
Revenue	$	219,660		$	35,581		$	255,241
Segment Loss	$	(887,831	)	$	(84,569	)	$	(972,400	)

Reconciliation of Segment Loss

Description	Amounts
Domestic loss	$	887,831
International loss		84,569
Corporate losses		2,320,784
Total	$	3,293,184

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 - Equity Method Investment

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE

– EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. Summarized financial information for Helomics is presented below:

Helomics Holdings Corporation

	For the three Months Ended
	March 31, 2019
Revenue	$	45,835

Gross margin	$	7,348


Net loss from continuing operations	$	(1,555,542	)

Net loss to investee	$	(1,166,656	) 1

The loss to investee was calculated at

75%

for the

three

-month period representing the ownership percentage in Helomics owned by other parties.

Note 3 - Revenue Recognition	3 Months Ended
Note 3 - Revenue Recognition	Mar. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 – REVENUE RECOGNITION Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. Customers may also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one -year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one -year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned. Warranty The Company generally provides one -year warranties against defects in materials and workmanship and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of March 31, 2019, and December 31, 2018, accounts receivable totaled $173,443 and $232,602, respectively. For the three months ended March 31, 2019, the Company did not incur material impairment losses with respect to its receivables. The Company deferred revenues related primarily to maintenance plans of $20,929 and $23,065 as of March 31, 2019 and December 31, 2018, respectively. Practical Expedients The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components.

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

– STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

2019

Registered Direct Offerings

March 1, 2019,

the Company completed a registered direct offering selling

1,385,000

shares of the Company’s common stock and warrants to purchase up to

692,500

shares of common stock. The common stock and warrants were sold in units with each unit consisting of

one

share of common stock and a warrant to purchase

0.5

of a share of common stock at an exercise price of

$1.00

per whole share. The units were sold at a price of

$0.90

per unit, resulting in gross proceeds to the Company of

$1,246,608,

before deducting expenses. The Company granted the underwriter unit purchase options, pursuant to which the Company granted the underwriter or its assignees the right to purchase from the Company up to an aggregate of

69,250

units and an exercise price equal to

125%

of the public offering price of the units in the offering, or

$1.125

per unit. The unit purchase options shall expire on

February 27, 2024.

March 29, 2019,

the Company completed a registered direct offering selling

1,478,750

shares of the Company’s common stock and warrants to purchase up to

739,377

shares of common stock. The common stock and warrants were sold in units with each unit consisting of

one

share of common stock and a warrant to purchase

0.5

of a share of common stock at an exercise price of

$1.00

per whole share. The units were sold at a price of

$0.80

per unit, resulting in gross proceeds to the Company of

$1,183,101,

73,937

units and an exercise price equal to

125%

of the public offering price of the units in the offering, or

$1.00

per unit. The unit purchase options shall expire on

March 27, 2024.

Increases in Authorized Shares

At the annual meeting on

December 28, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this increase was filed on

January 2, 2018.

At a special meeting of the stockholders on

March 22, 2019,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

50,000,000

100,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this measure was filed on

March 22, 2019.

At a special meeting of the stockholders on

March 22, 2019,

the stockholders approved an amendment to the Amended and Restated

2012

Stock Incentive Plan to (a) increase the reserve of shares of common stock authorized for issuance thereunder to

10,000,000,

(b) increase certain thresholds for limitations on grants, and (c) reapprove the performance goals thereunder.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

The Company has experienced

significant option exercises in its history. Beginning in

2019,

the Company began calculating the estimated volatility used in the Black-Scholes option valuation model based on the trading history of the Company’s own stock. Given the limited trading history of the Company’s common stock, the Company had previously used the volatility of comparable companies in order to value options and warrants granted in prior years.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.

Valuation and accounting for options and warrants

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.

For grants of stock option and warrants issued during the quarter ended

March 31, 2019,

the Company used

2.41%

2.76%

risk free interest rate,

dividend rate,

79.8%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.4112

$.7644

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		1,098,858			1.01		2,336,154			1.07
Expired		(194,564	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at December 31, 2018		3,669,277		$	1.70		3,626,643		$	4.17

Issued		459,169			0.73		2,325,406			0.92
Expired		(56,867	)		2.00		(919	)		603.89

Outstanding at March 31, 2019		4,071,579		$	1.59		5,951,130		$	3.29

March 31, 2019,

3,346,375

stock options are fully vested and currently exercisable with a weighted average exercise price of

$1.70

and a weighted average remaining term of

8.72

years. There are

4,750,221

warrants that are fully vested and exercisable. Stock-based compensation recognized for the

three

months ended

March 31, 2019

and

March 31, 2018

was

$263,600

and

$226,387,

respectively. The Company has

$130,839

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

March 31, 2019:

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.619		524,958		9.77
$	0.75		33,335		10.00
$	0.82		60,000		9.67
$	0.849		3,534		9.80
$	0.90		30,000		9.92
$	0.91		10,000		9.05
$	0.965		3,000		9.13
$	0.97		191,753		8.77
$	1.01		149,110		8.88
$	1.06		23,585		9.51
$	1.10		86,958		9.22
$	1.125		69,250		4.92
$	1.13		195,931		9.31
$	1.15		21,740		9.34
$	1.16		66,451		9.35
$	1.18		30,000		9.36
$	1.20		41,668		9.34
$	1.21		30,000		9.86
$	1.35		111,112		8.96
$	1.454		17,200		8.51
$	1.47		2,271,476		8.24
$	2.10		14,286		8.01
$	2.25		293		7.41
$	2.42		20,640		7.39
$	2.80		57,145		7.76
$	3.75		4,000		7.25
$	4.125		3,636		7.51
$	4.1975		7,147		7.47
$	4.25		3,529		7.01
$	5.125		3,902		7.44
$	65.75		190		6.56
$	73.50		1,157		6.76
$	77.50		2,323		6.25
$	80.25		187		6.51
$	86.25		232		6.01
$	131.25		81		3.44
$	148.125		928		3.97
$	150.00		1,760		3.38
$	162.50		123		5.76
$	206.25		121		5.51
$	248.4375		121		4.29
$	262.50		77		4.26
$	281.25		529		3.80
$	318.75		3		4.11
$	346.875		72		5.01
$	431.25		306		4.94
$	506.25		188		4.76
$	596.25		42		4.50

			4,071,579

Warrants
$	0.70		754,642		4.78
$	0.836		221,292		4.67
$	1.00		2,495,811		4.34
$	1.07		697,946		3.60
$	1.155		1,071,776		4.50
$	1.188		138,889		4.78
$	1.3125		86,086		4.51
$	2.25		385,000		2.82
$	123.75		94,084		1.42
$	243.75		2,529		0.35
$	309.375		2,850		0.86
$	309.50		223		0.60
			5,951,130

Stock Options and Warrants Granted by the Company

The following table is the listing of stock options and warrants as of

March 31, 2019

by year of grant:

Stock Options:
Year	Shares		Price
2011		173		$281.25
2012		1,841	131.25	–	150.00
2013		1,500	148.13	–	596.25
2014		836	162.50	–	431.25
2015		4,088	65.75	–	86.25
2016		100,294	2.25	–	5.13
2017		2,427,320	1.01	–	2.10
2018		1,076,358	0.62	–	1.35
2019		459,169	0.62	–	1.13
Total		4,071,579	$0.62	–	$596.25

Warrants:
Year	Shares		Price
2014		5,536	$243.75	–	$309.50
2015		94,151	0.00	–	243.75
2016		252,333		1.00
2017		1,082,946	1.07	–	2.25
2018		2,190,758	0.84	–	1.155
2019		2,325,406	0.704	–	1.19
Total		5,951,130	$0.00	–	$309.50

Note 5 - Notes Receivable	3 Months Ended
Note 5 - Notes Receivable	Mar. 31, 2019
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 – NOTES RECEIVABLE The Company has a secured promissory note receivable from CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of ( 8% ) on the principal amount. Unpaid principal and unpaid accrued interest on the note are due and payable on February 28, 2020. In 2019, CytoBioscience and its parent company, InventaBioTech, were current on all interest amounts due through April 2019. At this time the Company does not believe a reserve is needed. As of December 31, 2018, the Company had a principal balance of $1,165,013, plus interest of $39,092, due from Helomics. In January and February 2019, the Company advanced Helomics $305,000. In March 2019, the Company advanced $420,000 to Helomics and advanced an additional $250,000 in April 2019. The balance to date owed by Helomics is $2,140,013 plus interest. On the balance sheet there is a reduction to the loan of $1,190,967 due to the cumulative equity method investments losses incurred from Helomics ownership; see Note 2. There were no further advances to Helomics prior to the completion of the merger. Upon completion of the merger with Helomics all intercompany notes were eliminated; see Note 10.

Note 6 - Convertible Debt and Derivative Liability

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Convertible Debt and Derivative Liability [Text Block]

NOTE

– CONVERTIBLE DEBT AND DERIVATIVE LIABILITY

Effective

September 28, 2018,

the Company issued convertible secured promissory notes to

two

private investors in the original principal amount of an aggregate

$2,297,727

(the “bridge loan”). The Company has loaned

one

-half of the net proceeds to Helomics. The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the bridge loan. The securities purchase agreements with the investors also provided for a

second

investment of an aggregate of

$500,000

by the investors at the consummation of the Merger transaction with Helomics; however, the investors and the Company have agreed that the investors will

not

make the

second

investment. As additional consideration for the investment, the Company issued an aggregate

650,000

shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate

1,071,776

shares of the Company’s common stock at an exercise price of

$1.155

per share. Each warrant is exercisable by the investor beginning on the

six

-month anniversary of the effective date through the

fifth

-year anniversary thereof.

The bridge loan accrues interest at a rate of

per annum (with

twelve

months of interest guaranteed). The bridge loan is due on

September 28, 2019.

Upon the earlier to occur of an event of default or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its bridge loan into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i)

$1.00

and (ii)

70%

of the lowest volume-weighted average price (the “VWAP”) of the Company’s common stock during the

-trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that

may

be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate

2,678,328

shares.

Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using

70%

of the VWAP for the

trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the bridge loan will be convertible based on management’s expectation that additional financing will be required. The derivative liability initially recorded in

September 2018

was

$645,008.

The Company has recognized changes in the fair value of the derivative as unrealized gains and losses. The Company recognized an unrealized loss for the corresponding change in fair value of

$19,408

for the

three

-month period ended

March 31, 2019.

The fair value of the derivative liability as of

March 31, 2019

was

$292,153.

The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of

2.94%

over

five

years with a

59%

volatility rate and a calculated value per warrant of

.5361

resulting in a fair value of

$574,631.

Management concluded that the warrants and Inducement Shares qualify for equity classification. The proceeds from the bridge loan were allocated between the convertible note, warrants, and inducement shares based on the relative fair value of the individual elements.

Effective

February 7, 2019,

the Company entered into a Forbearance Agreement with each of the bridge loan investors pursuant to which, among other things, the investors agreed to forbear on their rights to accelerate the bridge loan based on an event of default and a claimed event of default. In connection with such forbearance, the Company issued Amended and Restated Senior Secured Promissory Notes that replaced the original agreement and, among other things, increased the aggregate principal amount of its indebtedness to the investors by

$344,659

to a balance of

$2,642,387.

Additionally, the investors received

166,667

inducement shares of the Company’s common stock, par value

$0.01

per share, valued at

$158,350,

increasing common stock and additional paid-in capital.

March 2019,

one

of the bridge loan investors twice converted a portion of the principal balance of the note. The investor converted

$90,000

from the principal balance and received

159,854

shares of the Company’s common stock. Additionally, pursuant to the bridge loan agreement, as a result of the

two

public offerings a portion of the principal balance was reduced by

$93,826.

The value of the embedded derivative from the bridge loan as well as the derivative included in the note payable agreements with the Company’s CEO (See – Note

) were based upon level

inputs – see the Fair Value Caption in Note

The flow table below discloses all changes in value of those derivative liabilities during the

three

-month period ended

March 31, 2019.

Derivative Liability Balance at December 31, 2018				Derivative Instrument Issued				Loss Recognized to Revalue Derivative Instrument at Fair Value				Adjustments to Derivative Liability for Warrants Issued				Derivative Liability Balance at March 31, 2019
$	272,745				69,722				19,408				8,665			$	353,210

Note 7 - Loss Per Share

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Three Months Ended March 31,
	2019			2018
Numerator
Net loss available in basic and diluted calculation	$	(3,293,184	)	$	(1,760,022	)
Comprehensive loss		(3,293,184	)		(1,760,022	)
Denominator:
Weighted average common shares outstanding-basic		15,731,517			11,383,217

Effect of diluted stock options warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic and diluted		15,731,517			11,383,217

Loss per common share-basic and diluted	$	(0.21	)	$	(0.15	)

(

) The number of shares underlying options and warrants outstanding as of

March 31, 2019

and

March 31, 2018

are

10,022,709

and

5,950,630,

respectively. The number of shares underlying the convertible debt as of

March 31, 2019

5,047,700.

The number of shares underlying the preferred stock as of

March 31, 2019

and

March 31, 2018

79,246.

The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Leases

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

Note

– LEASES

The Company’s corporate offices are located at

2915

Commers Drive, Suite

900,

Eagan, Minnesota

55121.

November 22, 2017,

the Company signed a

second

amendment to its lease last amended on

January 28, 2013.

The lease as amended has a

three

-year term effective

February 1, 2018

ending

January 31, 2021.

The Company leases

5,773

square feet at this location, of which

2,945

square feet is used for office space and

2,828

is used for manufacturing.

Skyline Medical Europe’s offices are located at

Chemin de la Fraite –

1380

Ohain, Belgium. The lease agreement was signed

April 24, 2018

and started on

June 15, 2018.

The Company leases around

2,000

square feet at this location,

750

of which is used for storage and

1,250

for office space. The lease is effective through

June 14, 2027.

Lease expense is

3,000

Euros per month.

Lease expense was

$29,212

and

$17,244

for the

three

months ended on

March 31, 2019

and

March 31, 2018,

respectively.

The following table summarizes other information related to our operating leases:

	March 31, 2019
Weighted average remaining lease term – operating leases in years		7.02
Weighted average discount rate – operating leases		8	%

The Company’s rent obligation for the next

five

years are as follows:

2019	$	60,060
2020		82,320
2021		43,320
2022		40,320
2023		40,320
2024 and thereafter		161,280
Total lease payments		427,620
Less interest		93,676
Present value of lease liabilities	$	333,944

Note 9 - Related Party Transactions	3 Months Ended
Note 9 - Related Party Transactions	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no revenue or expenses generated by this partnership to date. In April 2018, one of the Company’s directors, Richard L. Gabriel, executed a six -month consulting contract to help guide operations for the Company’s wholly-owned subsidiary TumorGenesis. Under the terms of the agreement Mr. Gabriel will receive $12,000 in monthly cash payments. In addition, Mr. Gabriel will receive a grant of 240,000 performance-based restricted stock units (“RSU’s”) under the Company’s Amended and Restated 2012 Stock Incentive Plan, with the vesting and payment of the RSU’s based on performance milestones as set forth in the agreement. As of this filing date Mr. Gabriel has not reached any of the prescribed milestones for earning performance based restricted stock units. Mr. Gabriel executed another six -month consulting contract for these services in October 2018. The contract has the same terms as the April 2018 contract except for the stock grants and performance milestones, which are covered under the original contract. On May 1, 2019, Mr. Gabriel executed a one -year contract with renewable three -month periods. Mr. Gabriel will receive $13,500 in monthly cash payments otherwise the contract remains the same as the previously signed agreement. On November 30, 2018, the Company’s CEO, Dr. Carl Schwartz, made an investment of $370,000 in the Company and received a note and a common stock purchase warrant for 221,292 warrant shares at $0.836 per share. As of January 8, 2019, Dr. Schwartz made an additional investment of $950,000 and received an amended and restated note in the original principal amount of $1,320,000 and an amended and restated warrant, which added a second tranche of 742,188 warrant shares at an exercise price of $0.704. Each tranche is exercisable beginning on the sixth month anniversary of the date of the related investment through the fifth -year anniversary of the date of the related investment. On January 8, 2019, Dr. Schwartz also purchased 78,125 shares of the Company’s common stock in a private investment for $50,000, representing a price of $0.64 per share, pursuant to a subscription agreement. On February 6, 2019, Dr. Schwartz made an additional investment of $300,000 in the Company and received an amended and restated note in the original principal amount of $1,620,000 and an amended and restated warrant, which added a third tranche of 138,889 warrant shares at an exercise price of $1.188 per share. Management concluded that the warrants qualified as equity classification. The proceeds from the loan from Dr. Schwartz were allocated between the note payable and warrants based on the relative fair value of the individual elements. On February 1, 2019 and the first day of each calendar month thereafter while the note and the warrant remain outstanding, a number of additional shares will be added to the second tranche and the third tranche equal to ( 1 ) one -half percent ( 1/2% ) of the outstanding principal balance of the Note on such date, divided by ( 2 ) the closing price of the Company’s common stock on that date. The Company has accounted for this liability to issue more warrants as a derivative liability as the exact number of warrants that will be issued was uncertain at the time of the agreement. The Company determined the fair value of this derivative liability by estimating the value and number of warrants that would be issued under various note payment scenarios. Based on this valuation, the Company recorded an initial derivative liability of $69,722. The Company issued 12,454 additional warrants to Dr. Schwartz under the agreement in February and March 2019, which reduced the value of the derivative liability by $8,665. As of March 31, 2019, the recorded derivative liability related to the agreement is $61,057.

Note 10 - Subsequent Events	3 Months Ended
Note 10 - Subsequent Events	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 – SUBSEQUENT EVENTS On April 4, 2019, the closing date, the Company acquired all of the outstanding common stock of Helomics. Helomics’ precision medicine services are designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy. This transaction will be accounted for as a business combination. The consideration for the remaining 75% of Helomics was approximately $7,822,632 , consisting of 4.0 million shares of common stock with a merger date valuation of $2,993,200 and 3.5 million shares of preferred stock with a merger date valuation of $2,619,050 . There was additional value of $2,210,382 for the extinguishment of the note due to the Company from Helomics. On the date of the transaction the Company’s previous 25% interest in Helomics was recorded as an equity method investment (see – Note 2 ). This investment had a recorded value of zero dollars due to the previous recognition of the portion of Helomics net loss attributable to the Company. On the day of the transaction the Company revalued the previous 25% investment at fair value using the consideration paid for the remaining 75% to determine the approximate fair value of the previous investment. As the result of this revaluation the Company recognized $2,607,544. Given the timing of the closing of this transaction, the Company is currently in the process of valuing the assets acquired and liabilities assumed in the business combination. As a result, the Company is not yet able to provide amounts to be recognized as of the closing date for the major classes of assets acquired and liabilities assumed and other related disclosures. Also, on the day of the transaction the Company issued 8,637,323 shares of common stock to extinguish notes payable from Helomics. The Company issued the noteholders 14,245,063 warrants as part of the debt extinguishment. The Company agreed to issue options for 900,000 shares of common stock to Helomics employees. The Company is not yet able to provide amounts to be recognized as of the closing date. On May 9, 2019, Dr. Schwartz advanced $75,000 to the Company. The loan earns 8% interest and is due in 60 days.

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

March 31, 2019,

the Company had

17,360,144

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

April 2009,

the Company received

510

(k) clearance from the Food and Drug Administration (the “FDA”) to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement. On

April 4, 2019,

the Company completed the acquisition and is now the sole owner of Helomics – see Note

10.

149,000

first

quarter of

2018,

is presented as part of the unaudited condensed consolidated financial statements (“financial statements”).

$66,401,129.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. In the

first

quarter the Company incurred negative cash flows from operations. Although the Company has attempted to curtail expenses, there is

guarantee that the Company will be able to reduce these expenses significantly, and expenses

may

need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.

The Company had cash and cash equivalents of

$1,124,730

as of

March 31, 2019

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-

with which the Company has raised approximately

$2.1

million in net proceeds in early

2019.

The Company

may

raise up to approximately

$5.0

million in additional gross proceeds, now that the Helomics acquisition is completed.

Since inception to

March 31, 2019,

the Company has raised approximately

$38,970,000

in equity and

$9,120,000

in debt financing. Equity raises include: a

January 2018

public offering with net proceeds of

$2,475,000;

and

March 2019

public offerings with net proceeds of

$1,112,000

and

$1,053,000.

Included in debt financing were raises in

September 2018

on senior secured promissory notes with net proceeds of

$1,815,000.

November 2018,

the Company received a loan from the CEO for

$370,000.

February 2019,

the Company received a loan from the CEO for

$950,000,

and in

March 2019

the Company received a loan from the CEO for

$300,000.

Interim Financial Statements, Policy [Policy Text Block]

Interim Financial Statements

-K filed with the SEC on

April 1, 2019.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

Accounting Policies and Estimates

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. The Company adopted the standard on

January 1, 2019,

using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. Upon adoption, the Company recognized

$353,007

of lease right-of-use (ROU) assets and liabilities for operating leases on its condensed consolidated balance sheet, of which,

$79,252

were classified as current liabilities. The adoption of ASU

2016

did

not

have a material impact on the Company’s consolidated results of operations or cash flows.

not

explicit in a lease, the Company utilizes its incremental borrowing rate for a period that closely matches the lease term.

See Note

– Leases

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	March 31, 2019		December 31, 2018

Finished goods	$	88,849	$	58,701
Raw materials		139,183		127,003
Work-In-Process		60,991		55,362
Total	$	289,023	$	241,066

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s fixed assets consist of the following:

	March 31, 2019		December 31, 2018
Computers and office equipment	$	205,758	$	204,903
Leasehold improvements		140,114		140,114
Manufacturing tooling		108,955		108,955
Demo equipment		74,529		85,246
Total		529,356		539,218
Less: Accumulated depreciation		380,647		358,765
Total Fixed Assets, Net	$	148,709	$	180,453

Depreciation expense was

$21,882

in the

three

months ended

March 31, 2019

and was

$14,496

for the

three

months ended

March 31, 2018.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was

$17,644

in the

three

months ended

March 31, 2019

and was

$3,671

in the

three

months ended

March 31, 2018.

The Company reviews identifiable intangible assets for impairment in accordance with ASC

360

—

Intangibles

—

Goodwill and Other

, whenever events or changes in circumstances indicate the carrying amount

may

not

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

There is

income tax provision in the accompanying statements of net loss due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2015

remain open to examination by federal and state tax authorities.

Offering Costs [Policy Text Block]

Offering Costs

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

one

financial institution. The Company has credit risk concentration for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.

Segment Reporting, Policy [Policy Text Block]

Segments

The Company has

two

operating segments; domestic and international sales. The segment revenues and net losses for the

three

-month period ended

March 31, 2019

are described in the table below. Substantially all of the Company’s revenues and expenses in the prior year were related to the domestic segment.

	Domestic			International			Totals
Revenue	$	219,660		$	35,581		$	255,241
Segment Loss	$	(887,831	)	$	(84,569	)	$	(972,400	)

Reconciliation of Segment Loss

Description	Amounts
Domestic loss	$	887,831
International loss		84,569
Corporate losses		2,320,784
Total	$	3,293,184

Risks and Uncertainties Policy [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Note 1 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	March 31, 2019		December 31, 2018

Finished goods	$	88,849	$	58,701
Raw materials		139,183		127,003
Work-In-Process		60,991		55,362
Total	$	289,023	$	241,066

Property Plant and Equipment Useful Life [Table Text Block]

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

Property, Plant and Equipment [Table Text Block]

	March 31, 2019		December 31, 2018
Computers and office equipment	$	205,758	$	204,903
Leasehold improvements		140,114		140,114
Manufacturing tooling		108,955		108,955
Demo equipment		74,529		85,246
Total		529,356		539,218
Less: Accumulated depreciation		380,647		358,765
Total Fixed Assets, Net	$	148,709	$	180,453

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Domestic			International			Totals
Revenue	$	219,660		$	35,581		$	255,241
Segment Loss	$	(887,831	)	$	(84,569	)	$	(972,400	)

Description	Amounts
Domestic loss	$	887,831
International loss		84,569
Corporate losses		2,320,784
Total	$	3,293,184

Note 2 - Equity Method Investment (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Equity Method Investments [Table Text Block]

	For the three Months Ended
	March 31, 2019
Revenue	$	45,835

Gross margin	$	7,348


Net loss from continuing operations	$	(1,555,542	)

Net loss to investee	$	(1,166,656	) 1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Share-based Payment Arrangement, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		1,098,858			1.01		2,336,154			1.07
Expired		(194,564	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at December 31, 2018		3,669,277		$	1.70		3,626,643		$	4.17

Issued		459,169			0.73		2,325,406			0.92
Expired		(56,867	)		2.00		(919	)		603.89

Outstanding at March 31, 2019		4,071,579		$	1.59		5,951,130		$	3.29

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.619		524,958		9.77
$	0.75		33,335		10.00
$	0.82		60,000		9.67
$	0.849		3,534		9.80
$	0.90		30,000		9.92
$	0.91		10,000		9.05
$	0.965		3,000		9.13
$	0.97		191,753		8.77
$	1.01		149,110		8.88
$	1.06		23,585		9.51
$	1.10		86,958		9.22
$	1.125		69,250		4.92
$	1.13		195,931		9.31
$	1.15		21,740		9.34
$	1.16		66,451		9.35
$	1.18		30,000		9.36
$	1.20		41,668		9.34
$	1.21		30,000		9.86
$	1.35		111,112		8.96
$	1.454		17,200		8.51
$	1.47		2,271,476		8.24
$	2.10		14,286		8.01
$	2.25		293		7.41
$	2.42		20,640		7.39
$	2.80		57,145		7.76
$	3.75		4,000		7.25
$	4.125		3,636		7.51
$	4.1975		7,147		7.47
$	4.25		3,529		7.01
$	5.125		3,902		7.44
$	65.75		190		6.56
$	73.50		1,157		6.76
$	77.50		2,323		6.25
$	80.25		187		6.51
$	86.25		232		6.01
$	131.25		81		3.44
$	148.125		928		3.97
$	150.00		1,760		3.38
$	162.50		123		5.76
$	206.25		121		5.51
$	248.4375		121		4.29
$	262.50		77		4.26
$	281.25		529		3.80
$	318.75		3		4.11
$	346.875		72		5.01
$	431.25		306		4.94
$	506.25		188		4.76
$	596.25		42		4.50

			4,071,579

Warrants
$	0.70		754,642		4.78
$	0.836		221,292		4.67
$	1.00		2,495,811		4.34
$	1.07		697,946		3.60
$	1.155		1,071,776		4.50
$	1.188		138,889		4.78
$	1.3125		86,086		4.51
$	2.25		385,000		2.82
$	123.75		94,084		1.42
$	243.75		2,529		0.35
$	309.375		2,850		0.86
$	309.50		223		0.60
			5,951,130

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Stock Options:
Year	Shares		Price
2011		173		$281.25
2012		1,841	131.25	–	150.00
2013		1,500	148.13	–	596.25
2014		836	162.50	–	431.25
2015		4,088	65.75	–	86.25
2016		100,294	2.25	–	5.13
2017		2,427,320	1.01	–	2.10
2018		1,076,358	0.62	–	1.35
2019		459,169	0.62	–	1.13
Total		4,071,579	$0.62	–	$596.25

Warrants:
Year	Shares		Price
2014		5,536	$243.75	–	$309.50
2015		94,151	0.00	–	243.75
2016		252,333		1.00
2017		1,082,946	1.07	–	2.25
2018		2,190,758	0.84	–	1.155
2019		2,325,406	0.704	–	1.19
Total		5,951,130	$0.00	–	$309.50

Note 6 - Convertible Debt and Derivative Liability (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

Derivative Liability Balance at December 31, 2018				Derivative Instrument Issued				Loss Recognized to Revalue Derivative Instrument at Fair Value				Adjustments to Derivative Liability for Warrants Issued				Derivative Liability Balance at March 31, 2019
$	272,745				69,722				19,408				8,665			$	353,210

Note 7 - Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31,
	2019			2018
Numerator
Net loss available in basic and diluted calculation	$	(3,293,184	)	$	(1,760,022	)
Comprehensive loss		(3,293,184	)		(1,760,022	)
Denominator:
Weighted average common shares outstanding-basic		15,731,517			11,383,217

Effect of diluted stock options warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic and diluted		15,731,517			11,383,217

Loss per common share-basic and diluted	$	(0.21	)	$	(0.15	)

Note 8 - Leases (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Lease, Cost [Table Text Block]

	March 31, 2019
Weighted average remaining lease term – operating leases in years		7.02
Weighted average discount rate – operating leases		8	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

2019	$	60,060
2020		82,320
2021		43,320
2022		40,320
2023		40,320
2024 and thereafter		161,280
Total lease payments		427,620
Less interest		93,676
Present value of lease liabilities	$	333,944

Note 1 - Summary of Significant Accounting Policies (Details Textual)				1 Months Ended					3 Months Ended
	Feb. 06, 2019 USD ($)	Jan. 08, 2019 USD ($)	Nov. 30, 2018 USD ($)	Mar. 31, 2019 USD ($) $ / shares shares	Feb. 28, 2019 USD ($)	Nov. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jan. 31, 2018 USD ($)	Mar. 31, 2019 USD ($) $ / shares shares	Mar. 31, 2018 USD ($)	Mar. 22, 2019 $ / shares	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 28, 2017 $ / shares
Common Stock, Shares, Outstanding, Ending Balance \| shares				17,360,144					17,360,144				14,091,748
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.01					$ 0.01		$ 0.01		$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance				$ (66,401,129)					$ (66,401,129)				$ (63,107,945)
Cash and Cash Equivalents, at Carrying Value, Ending Balance				1,124,730					1,124,730				162,152
Stockholders' Equity, Period Increase (Decrease), Total									38,970,000
Debt Instrument, Increase (Decrease), Net, Total									9,120,000
Operating Lease, Right-of-Use Asset				333,944					333,944
Operating Lease, Liability, Current				78,819					78,819
Depreciation, Total									21,882	$ 14,496
Amortization of Intangible Assets, Total									17,644	$ 3,671
Income Tax Expense (Benefit), Total									0
Unrecognized Tax Benefits, Ending Balance				0					0
Liability for Uncertainty in Income Taxes, Current				0					$ 0
Open Tax Year									2015 2016 2017 2018
Number of Operating Segments									2
Operating Lease, Liability, Total				333,944					$ 333,944
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset												$ 353,007
Operating Lease, Liability, Current												79,252
Operating Lease, Liability, Total												$ 353,007
Chief Executive Officer [Member]
Proceeds from Related Party Debt	$ 300,000	$ 950,000	$ 370,000	300,000	$ 950,000	$ 370,000
Convertible Promissory Note [Member]
Proceeds from Debt, Net of Issuance Costs							$ 1,815,000
S-3 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total									2,100,000
Issuance or Sale of Equity, Potentially Issuable				5,000,000					$ 5,000,000
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total								$ 2,475,000
First S-3 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total				1,112,000
Second S-3 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 1,053,000
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage										25.00%

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Finished goods	$ 88,849	$ 58,701
Raw materials	139,183	127,003
Work-In-Process	60,991	55,362
Total	$ 289,023	$ 241,066

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	3 Months Ended
	Mar. 31, 2019
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property, Plant, and Equipment Gross	$ 529,356	$ 539,218
Less: Accumulated depreciation	380,647	358,765
Total Fixed Assets, Net	148,709	180,453
Office Equipment [Member]
Property, Plant, and Equipment Gross	205,758	204,903
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	140,114
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 74,529	$ 85,246

Note 1 - Summary of Significant Accounting Policies - Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 255,241	$ 411,593
Segment Loss	(3,293,184)	(1,760,022)
Segment Loss	3,293,184	$ 1,760,022
Domestic [Member]
Revenue	219,660
Segment Loss	(887,831)
Segment Loss	887,831
International [Member]
Revenue	35,581
Segment Loss	(84,569)
Segment Loss	84,569
Domestic and International Segments [Member]
Segment Loss	(972,400)
Segment Loss	972,400
Corporate Segment [Member]
Segment Loss	(2,320,784)
Segment Loss	$ 2,320,784

Note 2 - Equity Method Investment (Details Textual)	Sep. 30, 2018
Helomics Holding Corp. [Member]
Equity Method Investment, Ownership Percentage	75.00%

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details)

3 Months Ended

Mar. 31, 2019

USD ($)

Revenue

$ 45,835

Gross margin

7,348

Net loss from continuing operations

(1,555,542)

Net loss to investee

$ (1,166,656)

^[1]

[1]	The loss to investee was calculated at 75% for the three-month period at the current equity investment percentage owned by the Company.

Note 3 - Revenue Recognition (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 173,443	$ 232,602
Contract with Customer, Liability, Current	$ 20,929	$ 23,065
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Mar. 22, 2019	Dec. 28, 2017	Jan. 29, 2017
Common Stock, Shares Authorized	100,000,000	100,000,000		100,000,000	100,000,000	50,000,000	24,000,000
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		79.80%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	3,346,375	3,346,375
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 1.70	$ 1.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term		8 years 262 days
Class of Warrant or Right Number of Warrants Vested and Exercisable	4,750,221	4,750,221
Share-based Payment Arrangement, Expense		$ 263,600	$ 226,387
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 130,839	$ 130,839
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.73		$ 1.01
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 240 days
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 309.50	$ 309.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.7644
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.41%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.4112
Amended and Restated 2012 Stock Incentive Plan [Member]
Common Stock, Shares Authorized					10,000,000
Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Equity Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		3 years
Warrants Issued With First 2019 Registered Direct Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	692,500	692,500
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.5	0.5
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1	$ 1
The First 2019 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues	1,385,000
Share Per Each Unit	1	1
Shares Issued, Price Per Share	$ 0.90	$ 0.90
Proceeds from Issuance or Sale of Equity, Total		$ 1,246,608
Right to Purchase Units, Assigned to Underwriters	69,250	69,250
Units, Exercise Price Percent of Offering Price	125.00%	125.00%
Class of Warrant or Right, Issued per Unit	1.125
The Second 2019 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues	1,478,750
Share Per Each Unit	1	1
Shares Issued, Price Per Share	$ 0.80	$ 0.80
Proceeds from Issuance or Sale of Equity, Total		$ 1,183,101
Right to Purchase Units, Assigned to Underwriters	73,937	73,937
Units, Exercise Price Percent of Offering Price	125.00%	125.00%
Class of Warrant or Right, Issued per Unit	1
Warrants Issued With Second 2019 Registered Direct Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	739,377	739,377
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.5	0.5
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1	$ 1

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Number of Shares Outstanding (in shares)	4,071,579
Warrant [Member]
Number of Shares Outstanding (in shares)	3,626,643	1,951,257
Average Exercise Price Outstanding (in dollars per share)	$ 4.17	$ 23.74
Number of Shares Issued (in shares)	2,325,406	2,336,154
Average Exercise Price Issued (in dollars per share)	$ 0.92	$ 1.07
Number of Shares Expired (in shares)	(919)	(10,706)
Average Exercise Price Expired (in dollars per share)	$ 603.89	$ 199.55
Number of Shares Exercised (in shares)		(650,062)
Average Exercise Price Exercised (in dollars per share)		$ 1
Number of Shares Outstanding (in shares)	5,951,130	3,626,643
Average Exercise Price Outstanding (in dollars per share)	$ 3.29	$ 4.17
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	3,669,277	2,764,983
Average Exercise Price Outstanding (in dollars per share)	$ 1.70	$ 2
Number of Shares Issued (in shares)	459,169	1,098,858
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.73	$ 1.01
Number of Shares Expired (in shares)	(56,867)	(194,564)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 2
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	4,071,579	3,669,277
Average Exercise Price Outstanding (in dollars per share)	$ 1.59	$ 1.70

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Shares, options (in shares)	4,071,579
Weighted average remaining life, options (Year)
Shares, warrants (in shares)	5,951,130
Weighted average remaining life, warrants (Year)
Warrant One [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 0.70
Shares, warrants (in shares)	754,642
Weighted average remaining life, warrants (Year)	4 years 284 days
Warrant Two [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 0.836
Shares, warrants (in shares)	221,292
Weighted average remaining life, warrants (Year)	4 years 244 days
Warrant Three [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 1
Shares, warrants (in shares)	2,495,811
Weighted average remaining life, warrants (Year)	4 years 124 days
Warrant Four [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 1.07
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	3 years 219 days
Warrant Five [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 1.155
Shares, warrants (in shares)	1,071,776
Weighted average remaining life, warrants (Year)	4 years 182 days
Warrant Six [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 1.188
Shares, warrants (in shares)	138,889
Weighted average remaining life, warrants (Year)	4 years 284 days
Warrant Seven [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 1.3125
Shares, warrants (in shares)	86,086
Weighted average remaining life, warrants (Year)	4 years 186 days
Warrant Eight [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 2.25
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	2 years 299 days
Warrant Nine [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 123.75
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	1 year 153 days
Warrant Ten [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	127 days
Warrant Eleven [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	313 days
Warrant Twelve [Member]
Warrant exercises, price per share (in dollars per share) \| $ / shares	$ 309.50
Shares, warrants (in shares)	223
Weighted average remaining life, warrants (Year)	219 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.619
Shares, options (in shares)	524,958
Weighted average remaining life, options (Year)	9 years 281 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.75
Shares, options (in shares)	33,335
Weighted average remaining life, options (Year)	10 years
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.82
Shares, options (in shares)	60,000
Weighted average remaining life, options (Year)	9 years 244 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.849
Shares, options (in shares)	3,534
Weighted average remaining life, options (Year)	9 years 292 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.90
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 335 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.91
Shares, options (in shares)	10,000
Weighted average remaining life, options (Year)	9 years 18 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.965
Shares, options (in shares)	3,000
Weighted average remaining life, options (Year)	9 years 47 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.97
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	8 years 281 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.01
Shares, options (in shares)	149,110
Weighted average remaining life, options (Year)	8 years 321 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.06
Shares, options (in shares)	23,585
Weighted average remaining life, options (Year)	9 years 186 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.10
Shares, options (in shares)	86,958
Weighted average remaining life, options (Year)	9 years 80 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.125
Shares, options (in shares)	69,250
Weighted average remaining life, options (Year)	4 years 335 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.13
Shares, options (in shares)	195,931
Weighted average remaining life, options (Year)	9 years 113 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.15
Shares, options (in shares)	21,740
Weighted average remaining life, options (Year)	9 years 124 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.16
Shares, options (in shares)	66,451
Weighted average remaining life, options (Year)	9 years 127 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.18
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 131 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.20
Shares, options (in shares)	41,668
Weighted average remaining life, options (Year)	9 years 124 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.21
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 313 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.35
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	8 years 350 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.454
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	8 years 186 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.47
Shares, options (in shares)	2,271,476
Weighted average remaining life, options (Year)	8 years 87 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.10
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	7 years 149 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.42
Shares, options (in shares)	20,640
Weighted average remaining life, options (Year)	7 years 142 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	7 years 277 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 3.75
Shares, options (in shares)	4,000
Weighted average remaining life, options (Year)	7 years 91 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	7 years 186 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	7 years 171 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	7 years 160 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 65.75
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	6 years 204 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	6 years 277 days
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	6 years 91 days
Stock Options Thirty-Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	6 years 186 days
Stock Options Thirty-Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Thirty-Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	3 years 160 days
Stock Options Thirty-Seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	3 years 354 days
Stock Options Thirty-Eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	3 years 138 days
Stock Options Thirty-Nine [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	5 years 277 days
Stock Options Forty [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 186 days
Stock Options Forty-One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	4 years 105 days
Stock Options Forty-Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 262.50
Shares, options (in shares)	77
Weighted average remaining life, options (Year)	4 years 94 days
Stock Options Forty-Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	3 years 292 days
Stock Options Forty-Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 40 days
Stock Options Forty-Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 3 days
Stock Options Fortysix [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	4 years 343 days
Stock Options Forty-seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	4 years 277 days
Stock Options Forty-eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	4 years 182 days

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	Mar. 31, 2019 $ / shares shares
Shares, options (in shares) \| shares	4,071,579
Shares, warrants (in shares) \| shares	5,951,130
Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 0.62
Warrant exercises, price per share (in dollars per share)	0
Maximum [Member]
Range of exercise prices, options (in dollars per share)	596.25
Warrant exercises, price per share (in dollars per share)	$ 309.50
Warrants 2014 [Member]
Shares, warrants (in shares) \| shares	5,536
Warrants 2014 [Member] \| Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] \| Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 309.50
Warrants 2015 [Member]
Shares, warrants (in shares) \| shares	94,151
Warrants 2015 [Member] \| Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 0
Warrants 2015 [Member] \| Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) \| shares	252,333
Warrant exercises, price per share (in dollars per share)	$ 1
Warrants 2017 [Member]
Shares, warrants (in shares) \| shares	1,082,946
Warrants 2017 [Member] \| Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] \| Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) \| shares	2,190,758
Warrants 2018 [Member] \| Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 0.84
Warrants 2018 [Member] \| Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 1.155
Warrants 2019 [Member]
Shares, warrants (in shares) \| shares	2,325,406
Warrants 2019 [Member] \| Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 0.704
Warrants 2019 [Member] \| Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 1.19
Stock Options 2011 [Member]
Shares, options (in shares) \| shares	173
Range of exercise prices, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) \| shares	1,841
Stock Options 2012 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) \| shares	1,500
Stock Options 2013 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 148.13
Stock Options 2013 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) \| shares	836
Stock Options 2014 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) \| shares	4,088
Stock Options 2015 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) \| shares	100,294
Stock Options 2016 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) \| shares	2,427,320
Stock Options 2017 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) \| shares	1,076,358
Stock Options 2018 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 0.62
Stock Options 2018 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 1.35
Stock Options 2019 [Member]
Shares, options (in shares) \| shares	459,169
Stock Options 2019 [Member] \| Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 0.62
Stock Options 2019 [Member] \| Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 1.13

Note 5 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended		2 Months Ended
Note 5 - Notes Receivable (Details Textual) - USD ($)	Apr. 30, 2019	Mar. 31, 2019	Feb. 28, 2019	Dec. 31, 2018	Mar. 31, 2018
Shelf Registration [Member] \| Subsequent Event [Member]
Financing Receivable, before Allowance for Credit Loss, Total	$ 2,140,013
Proceeds from Issuance or Sale of Equity, Total	250,000
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total					$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage					8.00%
Helomics Holding Corp. [Member]
Financing Receivable, before Allowance for Credit Loss, Total				$ 1,165,013
Interest Receivable				$ 39,092
Payments to Acquire Notes Receivable			$ 305,000
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Increase (Decrease) in Notes Payable, Current, Total	$ (1,190,967)
Helomics Holding Corp. [Member] \| Shelf Registration [Member]
Payments to Acquire Notes Receivable		$ 420,000

Note 6 - Convertible Debt and Derivative Liability (Details Textual)					1 Months Ended	3 Months Ended
	Mar. 31, 2019 USD ($) yr $ / shares	Feb. 07, 2019 USD ($) $ / shares shares	Oct. 26, 2018	Oct. 03, 2018 $ / shares shares	Mar. 31, 2019 USD ($) yr $ / shares shares	Mar. 31, 2019 USD ($) yr $ / shares	Mar. 31, 2018 USD ($)	Mar. 22, 2019 $ / shares	Dec. 31, 2018 $ / shares	Sep. 30, 2018 USD ($)	Sep. 28, 2018 USD ($)	Dec. 28, 2017 $ / shares
Stock Issued During Period, Shares, Inducement for Bridge Loan \| shares				650,000
Debt Instrument, Increase (Decrease), Net, Total						$ 9,120,000
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.01				$ 0.01	$ 0.01		$ 0.01	$ 0.01			$ 0.01
Stock Issued During Period, Value, Forebearance for Bridge Loan						$ 158,350
Debt Conversion, Converted Instrument, Amount						90,000
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total	$ 292,153				$ 292,153	292,153				$ 645,008
Unrealized Gain (Loss) on Derivatives						$ (19,408)
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 309.50				$ 309.50	$ 309.50
Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares				1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 1.155
Class of Warrant or Right, Vesting Period			180 days
Warrants and Rights Outstanding, Term				5 years
Class of Warrant or Right, Fair Value per Warrant \| $ / shares	$ 0.5361				$ 0.5361	$ 0.5361
Warrants and Rights Outstanding	$ 574,631				$ 574,631	$ 574,631
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0294				0.0294	0.0294
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input \| yr	5				5	5
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.59				0.59	0.59
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount											$ 2,297,727
Proceeds from Notes Payable, Total	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Debt Instrument, Term				1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock				70.00%
Debt Instrument, Convertible, Threshold Trading Days				20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares \| shares				2,678,328
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares				$ 1
Bridge Notes [Member]
Debt Instrument, Increase (Decrease), Net, Total		$ 344,659
Long-term Debt, Total		$ 2,642,387
Stock Issued During Period, Shares, Forebearance for Bridge Loan \| shares		166,667
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 2	$ 0.01			$ 2	$ 2
Stock Issued During Period, Value, Forebearance for Bridge Loan		$ 158,350
Debt Conversion, Converted Instrument, Amount					$ 90,000
Debt Conversion, Converted Instrument, Shares Issued \| shares					159,854
Increase (Decrease) in Notes Payable, Current, Total					$ (93,826)

Note 6 - Convertible Debt and Derivative Liability - Change in Fair Value of Derivative Liabilities (Details) - Fair Value, Inputs, Level 3 [Member]	3 Months Ended
	Mar. 31, 2019 USD ($)
Balance	$ 69,722
Warrant contingent interest	19,408
Unrealized loss	8,665
Unrealized gain	$ 353,210

Note 7 - Loss Per Share (Details Textual) - shares	3 Months Ended
Note 7 - Loss Per Share (Details Textual) - shares	Mar. 31, 2019	Mar. 31, 2018
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,022,709	5,950,630
Convertible Debt Securities [Member]
Weighted Average Number of Shares, Contingently Issuable	5,047,700
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Net loss available in basic and diluted calculation

$ (3,293,184)

$ (1,760,022)

Comprehensive loss

$ (3,293,184)

$ (1,760,022)

Weighted average common shares outstanding-basic (in shares)

15,731,517

11,383,217

Effect of diluted stock options warrants and preferred stock (1) (in shares)

^[1]

Weighted average common shares outstanding-basic and diluted (in shares)

15,731,517

11,383,217

Loss per common share - basic and diluted (in dollars per share)

$ (0.21)

$ (0.15)

[1]

The number of shares underlying options and warrants outstanding as of March 31, 2019 and March 31, 2018 are 10,022,709 and 5,950,630, respectively. The number of shares underlying the convertible debt as of March 31, 2019 is 5,047,700. The number of shares underlying the preferred stock as of March 31, 2019 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Leases (Details Textual)		3 Months Ended
Note 8 - Leases (Details Textual)	Jun. 15, 2018 EUR (€) ft²	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Feb. 01, 2018 ft²
Operating Leases, Rent Expense, Total \| $		$ 29,212	$ 17,244
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract				3 years
Area of Real Estate Property				5,773
Corporate Office, Minnesota [Member] \| Office Space [Member]
Area of Real Estate Property				2,945
Corporate Office, Minnesota [Member] \| Manufacturing Facility [Member]
Area of Real Estate Property				2,828
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property	2,000
Lessee, Operating Lease, Monthly Rent \| €	€ 3,000
Skyline Medical Europe’s Offices Lease [Member] \| Office Space [Member]
Area of Real Estate Property	1,250
Skyline Medical Europe’s Offices Lease [Member] \| Storage Space [Member]
Area of Real Estate Property	750

Note 8 - Leases - Lease Information (Details)	Mar. 31, 2019
Weighted average remaining lease term – operating leases in years (Year)	7 years 7 days
Weighted average discount rate – operating leases	8.00%

Note 8 - Leases - Rent Obligation (Details)	Mar. 31, 2019 USD ($)
2019	$ 60,060
2020	82,320
2021	43,320
2022	40,320
2023	40,320
2024 and thereafter	161,280
Total lease payments	427,620
Less interest	93,676
Present value of lease liabilities	$ 333,944

Note 9 - Related Party Transactions (Details Textual) - USD ($)					1 Months Ended				2 Months Ended	3 Months Ended		6 Months Ended
	Feb. 06, 2019	Feb. 01, 2019	Jan. 08, 2019	Nov. 30, 2018	Mar. 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Apr. 30, 2018	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Sep. 30, 2018
Proceeds from Issuance of Common Stock										$ 2,479,709	$ 2,959,509
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total					$ 292,153				$ 292,153	292,153		$ 292,153	$ 645,008
Schwartz Warrant First Tranche [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				221,292			221,292
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.836			$ 0.836
Schwartz Warrant Third Tranche [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	138,889
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.188
Schwartz Warrant [Member]
Class of Warrant or Right, Additional Shares Increase, Percentage		0.50%
Director [Member]
Related Party Transaction, Contract Term								6 years				180 days
Related Party Transaction, Monthly Cash Payment										$ 12,000		$ 13,500
Director [Member] \| Restricted Stock Units (RSUs) [Member]
Stock Issued During Period, Shares, New Issues										240,000
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues			78,125
Proceeds from Related Party Debt	$ 300,000		$ 950,000	$ 370,000	300,000	$ 950,000	$ 370,000
Due to Related Parties, Total			1,320,000
Proceeds from Issuance of Common Stock			$ 50,000
Shares Issued, Price Per Share			$ 0.64
Chief Executive Officer [Member] \| Schwartz Note [Member]
Debt Instrument, Face Amount	$ 1,620,000
Chief Executive Officer [Member] \| Schwartz Warrant Second Tranche [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			742,188
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.704
Chief Executive Officer [Member] \| Schwartz Warrant [Member]
Class of Warrant or Right Issued During Period									12,454
Chief Executive Officer [Member] \| Schwartz Warrant [Member] \| Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total				$ 69,722	$ 61,057		$ 69,722		$ 61,057	$ 61,057		$ 61,057
Derivative Liability, Change in Fair Value Due to Issuance of Warrants									$ (8,665)

Note 10 - Subsequent Events (Details Textual) - USD ($)			3 Months Ended
Note 10 - Subsequent Events (Details Textual) - USD ($)	May 09, 2019	Apr. 04, 2019	Mar. 31, 2019	Mar. 31, 2018	Apr. 03, 2019
Proceeds from Issuance of Debt			$ 1,250,000
Subsequent Event [Member] \| Loans From Dr. Schwartz [Member] \| Chief Executive Officer [Member]
Proceeds from Issuance of Debt	$ 75,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Helomics Acquisition, Inc. [Member] \| Subsequent Event [Member]
Business Acquisition, Percentage of Voting Interests Acquired		75.00%			25.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		8,637,323
Gain (Loss) on Extinguishment of Debt, Total		$ 2,210,382
Business Acquisition, Revaluation, Gain (Loss) on Acquisition		$ 2,607,544
Helomics Acquisition, Inc. [Member] \| Subsequent Event [Member] \| Warrants Issued to Holders of Helomics Notes and Warrants [Member]
Class of Warrant or Right Issued During Period		14,245,063
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 900,000
Helomics Acquisition, Inc. [Member] \| Subsequent Event [Member] \| Common Stock [Member]
Business Combination, Consideration Transferred, Total		$ 7,822,632
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		4,000,000
Business Combination, Merger Date Valuation		$ 2,993,200
Helomics Acquisition, Inc. [Member] \| Subsequent Event [Member] \| Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		3,500,000
Business Combination, Merger Date Valuation		$ 2,619,050